secwatch.observer — SEC 8-K summary
======================================

Issuer:     Stoke Therapeutics, Inc. (STOK)
CIK:        0001623526
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0000950170-25-107275
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Stoke Q2 net loss $23.5M; Phase 3 EMPEROR dosed, 3-year OLE data show durability
--------------------------------------------------------------------------------

- Net loss $23.5M ($0.40/sh) for Q2 2025 vs $25.7M loss in Q2 2024; H1 net income $89.4M from Biogen collaboration.
- First patient dosed in global Phase 3 EMPEROR study of zorevunersen for Dravet syndrome; sites active in US, UK, Japan.
- New 3-year OLE data show durable seizure reductions and continued improvements in cognition/behavior.
- Phase 1 OSPREY study of STK-002 initiated for Autosomal Dominant Optic Atrophy (ADOA).
- Cash $355M as of June 30, 2025, expected to fund operations to mid-2028 and into launch readiness.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1623526/000095017025107275/0000950170-25-107275-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1623526/000095017025107275/stok-20250812.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-107275

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer